Nexalin Technology, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Nexalin Technology, Inc. (NXL) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 6.00% for the 12-month period ending 2023-12-31, per its 10-K/A filed 2025-09-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-09-23
- Nexalin Technology, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was 6.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2023-12-31 | 6.00% 10-K/A · filed 2025-09-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| EDAP TMS SA (FOCL) | $0.171B | ||
| IRIDEX CORP (IRIX) | United States | $0.011B |